Directed differentiation of human pluripotent stem cells (hPSCs) into cardiomyocytes typically produces cells with structural, functional, and biochemical properties that most closely resemble those present in the fetal heart. Here we establish an in vitro engineered developmental cardiac niche to produce matured hPSC-derived cardiomyocytes (hPSC-CMs) with enhanced sarcomere development, electrophysiology, contractile function, mitochondrial capacity, and a more mature transcriptome. When this developmental cardiac niche was applied to dystrophin mutant hPSC-CMs, a robust disease phenotype emerged, which was not observed in nonmatured diseased hPSC-CMs. Matured dystrophin mutant hPSC-CMs exhibited a greater propensity for arrhythmia as measured via beat rate variability, most likely due to higher resting cytosolic calcium content. Using a custom nanopatterned microelectrode array platform to screen functional output in hPSC-CMs exposed to our engineered developmental cardiac niche, we identified calcium channel blocker, nitrendipine, mitigated hPSC-CM arrhythmogenic behavior and correctly identified sildenafil as a false positive. Taken together, we demonstrate our developmental cardiac niche platform enables robust hPSC-CM maturation allowing for more accurate disease modeling and predictive drug screening.
INTRODUCTION
Cardiovascular disease remains the leading cause of death for both men and women worldwide, with a rapidly growing impact on developing nations 1 . Inherited cardiomyopathies are the major cause of heart disease in all age groups, including children and young, otherwise healthy adults 2 . Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) are a promising tool for studying cardiomyopathy because they vastly increase the accessibility to human cardiomyocytes that can theoretically express the full array of ion channels, protein isoforms, and genetic and metabolic machinery found in the human heart 3 . A major goal of current cardiac disease modeling efforts is to gain insight into the onset and progression of cardiomyopathies as a first step towards designing more effective therapeutic strategies. Many patients with inherited cardiomyopathies, however, do not present with cardiac symptoms until late adolescence or early adulthood 2 . This limits the potential of hPSC-CM disease modeling since current differentiation protocols produce cardiomyocytes with structural, functional, and biochemical properties that most closely resemble cells of the fetal heart 4 .
Developmental maturation presents a technical hurdle for hPSC-CMs in cardiac disease models. To date, hPSC-CMs exhibiting a fetal-like phenotype have been used to study channelopathies [5] [6] [7] , metabolic syndromes 8 , hypertrophic and dilated cardiomyopathies 9, 10 , as well as other delayed-onset cardiac diseases such as Duchenne Muscular Dystrophy (DMD) cardiomyopathy 11, 12 . While such reports have certainly been groundbreaking and valuable 13 , the majority of the findings are based on the performance of cardiomyocytes that are still quite naive, having incomplete structural organization, and a mixture of fetal and adult protein isoform expression. Much effort has been invested to develop methods to accelerate the development of hPSC-CMs 4, 13 . While such strategies have proven to be effective at enhancing specific aspects of hPSC-CM development, it is unlikely that a single method can fully recreate the developing cardiac microenvironmental niche. We therefore generated a multifaceted and combinatorial maturation (ComboMat) strategy, incorporating nanotopographic substrate cues, thyroid hormone T3, and Let-7i miRNA overexpression aimed at more comprehensively mimicking the developmental cardiac niche in order to accelerate the maturation of hPSC-CMs in vitro. Anisotropic extracellular matrix cues, critical for proper structure-function relationship in the fully developed heart and morphological development in hPSC-CMs 14 , have also been found to be an important factor during cardiac development and looping 15 . Thyroid hormone treatment, simulating the spike in serum T3 levels immediately following birth, has been shown to improve force production and calcium handling in hPSC-CMs 16 , while upregulation of Let-7 miRNAs enhance metabolic development in hPSC-CMs 17 .
As a means to highlight the utility of a mature cardiac phenotype for in vitro cardiac tissue engineering applications, we set out to develop a more mature model of dystrophic cardiomyopathy. Dystrophic cardiomyopathies, such as Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), are X-linked genetic disorders resulting from a mutated dystrophin gene. Cardiac complications have replaced respiratory failure as the leading cause of death in DMD patients due to the emergence of supportive ventilation as a standard of care 18 .
However, cardiomyopathy in dystrophic rodent models, such as the mdx mouse, have proven to be poor predictors of patients' responses to therapeutic treatment in the clinic 19, 20 . In fact, a recent clinical trial with sildenafil, which showed promise in alleviating cardiac dysfunction in the mdx mouse 21 , exacerbated cardiac symptoms in DMD patients and had to be terminated early 20 .
Thus, an unmet medical need exists for improved human models of dystrophic cardiomyopathy.
We previously reported that dystrophin mutant human cardiomyocytes displayed phenotypic differences compared to healthy controls, but these differences were mild or were induced by exogenous acute stress, such as hypotonic challenge 11, 22 . Other dystrophin mutant models, developed by Lin et al. 12 and Young et al. 23 , provide valuable insight into DMD-specific disease mechanisms and potential therapeutic treatment options, but are based on fetal-like hPSC-CMs.
We hypothesize that more mature hPSC-CMs will improve the predictive power of preclinical screening models of dystrophic cardiomyopathy and create an in vitro phenotype more similar to that found in patients.
To test this hypothesis, we applied our ComboMat strategy to CRISPR-generated dystrophin mutant (DMD 263delG) hPSC-CMs in order to facilitate the manifestation of adultonset cardiac disease phenotypes in vitro. Patients with similar exon 1 mutations in the DMD gene ( Supplementary Fig. 1 ) express a truncated dystrophin protein and present with a BMD phenotype 24 . When matured using our combinatorial maturation strategy, DMD mutant hPSC-CMs exhibit a much greater propensity for arrhythmia, as measured using our custom nanopatterned multielectrode array (nanoMEA) cardiac screening platform. Without developmental cardiac niche cues, we could not distinguish the functional profile of DMD mutant hPSC-CMs from healthy isogenic control cells. Thus, the ComboMat platform produced more physiologically relevant hPSC-CMs for disease modeling and drug screening applications.
RESULTS

Profiling the transcriptome of ComboMat-treated cardiomyocytes
We investigated the combinatorial impact of three distinct cues, biomimetic nanopatterned topography (NP) 14, 15 , thyroid hormone T3 (T3) 16 , and Let7i miRNA overexpression (Let7i) 17 , incorporated into a single procedure termed the ComboMat platform (schematically depicted in Fig. 1a ). We performed RNA-seq to look at the whole transcriptome of hPSC-CMs exposed to different combinations of the three maturation cues. Principal component analysis (Fig. 1b) demonstrated that the ComboMat group (all three factors combined together) separated from all other conditions. Next, we generated an enrichment heat map that consists of seven hallmark pathways of cardiomyocyte maturation, (Fig. 1c) . As more maturation conditions were layered on top of one another, cardiomyocytes appeared to be progressively more mature. The ComboMat group showed the most robust maturation, with up-regulation in six of the pathways and down-regulation in the cell cycle pathway. Figure 1d shows 8 up-regulated gene ontology (GO) terms based on P-value between the ComboMat and Control (Empty Vector cells on flat surfaces; EV-Flat) groups. Pathways related to metabolism such as glucose metabolic processes, long-chain fatty acid import, and glycolytic process were up-regulated. GO terms associated with muscle processes including muscle tissue development, muscle contraction, and striated muscle cell differentiation were also up-regulated.
We generated a bubble plot ( Fig. 1e) to compare gene expression of the ComboMat and Control groups along PC1. We found 53 genes that were significantly higher and 13 genes that were significantly lower in both Adult vs. Fetal and ComboMat vs. Control. The gene that was most up-regulated along PC1 in the ComboMat group was Hair Growth Associated gene (HR), a thyroid hormone co-repressor. Krupel-like factor (KLF9), a transcription factor, was also significantly up-regulated. KLF9 has been reported to bind to the PPARγ promoter, a critical gene in fatty acid metabolism 25 . Cytochrome c oxidase subunit 6A2 (COX6A2), another gene associated with cardiac metabolism, was also up-regulated in the ComboMat group. 
Structural maturation of ComboMat-treated cardiomyocytes
For these studies, and all subsequent functional assays, we compared the full ComboMat platform (Let7i+NP+T3) to a viral vector Control (EV+Flat+No T3) and each maturation cue in isolation: NP (EV+NP+No T3), T3 (EV+Flat+T3), and Let7i (Let7i+Flat+No T3).
Immunofluorescence imaging ( Fig. 2a) confirmed that hPSC-CMs cultured on NPs elongated in the direction of the nanotopography and exhibited more anisotropic, rod-shaped morphologies.
Sarcomeres developed with a higher degree of directionality and order on NPs, resulting in more sarcomeres in register with one another (Fig. 2b) . Compared to Control, hPSC-CMs exposed to just T3 or Let7i were significantly larger ( Fig. 2f) but formed rounded or irregular morphologies. When exposed to all three cues in the ComboMat platform, hPSC-CMs became rod-shaped and were larger than with each cue in isolation ( Fig. 2f , *p < 0.05). hPSC-CMs The ultrastructure of the hPSC-CMs was investigated via transmission electron microscopy (TEM). We found that hPSC-CMs exposed to Control conditions exhibited low density, disorganized myofibrils and only punctate Z-body formation (Fig. 2b) . The application of NPs, T3, or Let7i individually improved the development of more organized and wider Z-bands ( Fig. 2d ) but overall sarcomeres remained rather disorganized and at a low density. In contrast, hPSC-CMs cultured with the ComboMat platform developed much more ordered sarcomeres, with the emergence of Z-bands and H-zones ( Fig. 2b) . Z-band width in cells, an indicator of myofibril bundling, was also significantly larger in the ComboMat group than Control or each cue in isolation.
Electro-mechanical and metabolic maturation of ComboMat-treated cardiomyocytes
To test if the genetic and structural changes imparted by the ComboMat platform manifested into enhanced functional performance of the hPSC-CMs, we employed two noninvasive measurements of electromechanical function. Using correlation-based contraction quantification (CCQ) 22 , we measured contractions of hPSC-CM monolayers paced at 1 Hz and filmed at 30 frames per second. By spatially averaging these contraction vectors together, we measured maximum contraction and relaxation velocities (annotated as red and blue marks in Fig. 3a ) for the Control, NP, T3, Let7i, and ComboMat conditions and found that cells exposed to the ComboMat platform had significantly faster contractions compared to Control or any maturation cue in isolation ( Fig. 3b) . To help explain this, we examined the angles of displacement during contractions and found that hPSC-CMs cultured on NPs contract in a more uniform direction than cells cultured on flat substrates ( Fig. 3c) . To quantify this preferred directionality, we measured the contraction anisotropic ratio (AR) and found that cells on NPs, such as those in the ComboMat platform, had a contraction magnitude over two times greater in the direction parallel with the underlying nanotopography than perpendicular to it (ComboMat AR = 2.39 ± 0.01) ( Fig. 3d) . This was in contrast to cells grown on traditional flat substrates, where contractions were randomly oriented, and exhibited similar magnitudes in all directions (Control AR = 1.04 ± 0.02).
In addition to contraction dynamics, we also measured cardiomyocyte electrical activity using microelectrode arrays (MEAs). An ion permeable resin, Nafion, was used to generate nanotopographic surfaces on MEAs (nanoMEAs) in order to facilitate hPSC-CM alignment in NP and ComboMat conditions while still enabling high resolution electrophysiological data capture from underlying electrodes. Figure 3e shows temporally averaged field potential recordings from Control and ComboMat cultures. Measuring spontaneous electrical activity of cardiac monolayers, we found that hPSC-CMs exposed to the ComboMat platform had significantly longer field potential durations than the Control, NP, and T3 groups ( Fig. 3f) . Additionally, the ComboMat platform significantly slowed the beat rate of the cardiomyocytes compared to Control or each maturation cue in isolation ( Fig. 3g) . hPSC-CMs exposed to the ComboMat platform also exhibited faster upstroke velocity as measured via patch clamp ( Supplementary   Fig. 2 
)
RNA-seq analysis suggested significant changes to cardiac metabolism imparted by the ComboMat platform. Thus, we probed the ability of the cardiomyocytes to utilize exogenous fatty acids via the "Palmitate assay" on a Seahorse mitochondrial flux analyzer ( Fig. 3h) . We found that hPSC-CMs exposed to the ComboMat platform exhibited significantly greater maximum change in oxygen consumption rate (OCR) measured between palmitate concentrations of 200 µM and 400 µM. (Fig. 3i) . Maximum respiratory capacity was also significantly greater in the ComboMat group compared to Control (Supplementary Fig. 3 )
ComboMat-treated dystrophin-mutant hPSC-CMs manifest disease phenotype
To begin, we tested whether DMD mutant hPSC-CMs responded in a similar manner to the ComboMat platform as their Normal (UC3-4) isogenic counterparts. Using the Seahorse MitoStress assay ( Fig. 4a) , we found that DMD mutant hiPSC-CMs had an increased maximum respiratory capacity when cultured under the ComboMat platform compared to Control conditions ( Fig. 4b) . Within the Control or ComboMat conditions, however, there was no statistical difference between the Normal and DMD mutant groups. The baseline electrophysiological characteristics of the DMD mutant cells were measured using our custom nanoMEA platform. The beat rate of the DMD mutant hiPSC-CMs decreased in response to the ComboMat platform to the same extent as the Normal hPSC-CMs ( Fig. 4c) . Additionally, the field potential duration (FPD) of DMD mutant hPSC-CMs increased when exposed to ComboMat compared to Control, mirroring observations made from Normal hPSC-CMs ( Fig.   4d ). From a structural standpoint, the DMD mutant hiPSC-CMs developed a characteristic elongated morphology with in-register sarcomeres when exposed to the ComboMat platform, whereas DMD mutant hiPSC-CMs exposed to Control conditions were more rounded, with more disorganized sarcomeres ( Fig. 4e ).
We hypothesized that by inducing hypertrophy and overall cardiomyocyte maturation, dystrophic hPSC-CMs would undergo greater mechanical stress and cellular damage, resulting in irregular functional activity, which would be absent in immature cells. We used the nanoMEA platform to record the electrical activity of spontaneously beating monolayers of the isogenic pair of Normal and DMD mutant hPSC-CMs exposed to Control or ComboMat conditions. Using a method of arrhythmia detection relying on beat rate variability 26 , we found that DMD mutant hPSC-CMs exposed to the ComboMat platform were significantly more arrhythmogenic than less mature DMD mutant hPSC-CMs in the Control condition. Figure 5a shows representative field potential traces from DMD mutant hPSC-CMs exposed to Control (black) or ComboMat (red) conditions with individual beat intervals annotated. By measuring the difference in time of the beat interval from one beat to the next (ΔBI) and plotting this change for 30 consecutive beats ( Fig. 5b) , we found that matured DMD mutant hPSC-CMs had a striking instability in beat rate. By measuring the percentage of beats with a ΔBI > 250 ms ( Fig. 5c ) and the arithmetic mean for ΔBI over 30 consecutive beats ( Fig. 5d) , we saw relatively large changes in beat intervals indicative of a more arrhythmogenic state. Without an autonomous nervous system in vitro, hPSC-CMs should develop a steady beating pattern without much variation from beat to beat. This steady behavior is apparent in the Control conditions for both normal and DMD cardiomyocytes as well as in healthy mature Normal cells ( Fig. 5b) . Importantly, we found that the full ComboMat platform is necessary to observe functional differences between Normal and DMD mutant hPSC-CMs. When the maturation cues are applied in isolation, there is no separation between the healthy Normal cells and the DMD mutant hPSC-CMs ( Supplementary   Fig. 4 
)
To identify a potential mechanism for this beat rate variability, we measured intracellular calcium (Ca 2+ ) using the ratiometric Ca 2+ indicator Fura-2 on an IonOptix imaging setup calibrated to calculate nanomolar intracellular Ca 2+ concentrations. Figure 5e depicts representative Ca 2+ traces from DMD mutant hPSC-CMs exposed to Control or ComboMat conditions. Matured DMD mutant hPSC-CMs were found to have an elevated baseline, or diastolic resting Ca 2+ level, compared to the less mature cells in the Control group. Quantifying this diastolic Ca 2+ level, we found a similar trend to the electrical instability presented previously.
Normal and DMD mutant hPSC-CMs in the Control groups had cytosolic Ca 2+ levels that were not statistically different from one another ( Fig. 5f) . DMD mutant hPSC-CMs matured using the ComboMat platform, however, have an elevated cytosolic Ca 2+ concentration compared to Normal hPSC-CMs.
Phenotypic drug screen using mature hPSC-CMs
In order to identify potential drug targets or classes of drugs for a more detailed phenotypic drug screen, we first performed a preliminary medium throughput, semi-automated screen with a small library of 2,000 diverse molecules with various mechanisms of action. Intracellular ATP (a widely used assay of cell viability in high throughput screens) was measured in DMD mutant hPSC-CMs after hypotonic stress. Overall the Z-prime of the assay was 0.71. The 8,000 data points (2,000 compounds at 4 concentrations) were ranked and plotted based on the Z-score ( Fig. 6a) . Taking into consideration the Z-score ranking (>3), standard deviation of replicates, and escalating dose-ranging response, 39 hits were identified from the 2000 input compounds (~2% hit rate) ( Supplementary Table 1 ). Of these hits, 9 (~23%) were classified as Ca 2+ channel blockers.
Incorporating this preliminary drug screen data with our findings of elevated intracellular Ca 2+ content (Fig. 5f) , we sought to utilize the nanoMEA platform to test whether nitrendipine (highlighted with blue box in Fig. 6a ), a dihydropyridine Ca 2+ channel blocker, could reduce the arrhythmogenic behavior of the mature DMD mutant hiPSC-CMs. We also tested sildenafil, an agent previously demonstrated not to benefit DMD patients 20 . Even at an early time point (four day ComboMat exposure) there was a significant difference in baseline beat rate variability between mature Normal hPSC-CMs and DMD mutant hPSC-CMs, while immature cells were indistinguishable from each other ( Fig. 6b) . We then exposed cells to various concentrations of nitrendipine or sildenafil citrate for seven days and measured their beat rate variability. Figure 6c,d show the dose-response curves for nitrendipine and sildenafil, respectively. Nitrendipine significantly reduced the Mean ΔBI in mature DMD mutant hPSC-CMs compared to DMSO carrier control. Doses up to 1 µM nitrendipine restored beat rate variability to levels within physiologically relevant ranges (<50 ms). Higher doses, however, ceased spontaneous beating. In contrast, sildenafil had no effect on beat rate variability, regardless of the dose. Neither nitrendipine nor sildenafil had a significant impact on beat rate variability for cells exposed to Control conditions or Normal hPSC-CMs exposed to the ComboMat platform. The benefits of nitrendipine were washed out within 48 hours if removed from the cell culture medium (Fig. 6e) . Ca 2+ imaging revealed that 100 nM nitrendipine reduced the diastolic Ca 2+ content in the mature DMD mutant hPSC-CMs compared to DMSO control ( Fig. 6f,g) . Nitrendipine had no impact on the diastolic Ca 2+ content in cells exposed to the Control condition ( Fig. 6g ).
DISCUSSION
The ComboMat platform proved to be a powerful tool in modulating cardiomyocyte development in vitro, increasing cell area, producing longer resting sarcomere lengths, and achieving more physiologically relevant binucleation percentages. Many of the functional enhancements that we observed from the ComboMat platform were predicted by our RNAseq analysis. GO terms for muscle development and contraction were upregulated in the ComboMat group, which resulted in faster contraction kinetics as measured by our CCQ contraction mapping. Metabolic GO terms such as fatty acid import were also upregulated in the ComboMat group and we found subsequently that cells exposed to the ComboMat group had a larger maximum respiratory capacity and ability to utilize exogenous fatty acids. Thus, there was agreement between the transcriptional and functional changes imparted by the ComboMat platform providing validation of our methods.
An important aspect of the present work is the development of a successful phenotypic drug screen platform. Methods such as the ComboMat platform, in conjunction with the nanoMEA electrophysiological screening system, can be scaled up for higher throughput screens of novel compounds. The noninvasive measurements can be used to monitor cell function longitudinally and the strong stratification of disease phenotype allows for easy comparison to healthy controls to see if drug treatment correlates with a restoration of function.
We were able to validate that Ca 2+ channel blockers were indeed a true hit from our initial screen as well as correctly weed out a false positive drug hit from mdx mouse model studies 20 .
Previous hPSC-CM models of dystrophic cardiomyopathy have relied heavily on hypotonic challenge to bring out a measurable disease phenotype 11, 23 . While effective, hypotonic challenge is not physiologically accurate and is only a transient insult. Here we show that by maturing the DMD mutant hPSC-CMs with the ComboMat platform, cells present with beat rate variability due in part to calcium overload. Along with its involvement in mediating cell injury through reactive oxygen species (ROS) and mitochondrial apoptosis signaling pathways 27 , Ca 2+ overload has long been known to mediate cardiac arrhythmias 28 and has been implicated both in vitro and in vivo to be a driving force behind DMD pathophysiology 29 . Thus, we have demonstrated a maturation-dependent disease phenotype in DMD mutant hPSC-CMs that recreates an early disease phenotype found in patients. This is an important distinction from previous DMD disease models and one that we believe represents a logical progression in the improved their ability to model heart failure 31 . Based on our findings, we propose that other cardiomyopathies may be more faithfully modeled by using hPSC-CMs matured beyond the typical fetal stage of standard directed differentiation methods.
While it is known that DMD patients exhibit diastolic dysfunction and arrhythmias, the pathogenesis of this disease phenotype is not fully understood 18 . Ca 2+ overload has long been postulated to play a central role in the pathophysiology of dystrophic cardiomyopathy 29 . Leaky Ca 2+ channels on the cell membrane and sarcoplasmic reticulum, abnormal NO signaling, and tears in the sarcolemma have all been proposed as the means for Ca 2+ entry into the cell but no consensus exists. The present model, with an endogenous electrophysiological disease phenotype due to elevated Ca 2+ levels, could prove to be a valuable tool for addressing some of these questions. Taken together, the present data show that cardiac maturation is an important factor in accurately modeling adult onset diseases, such as DMD cardiomyopathy, and that the ComboMat platform is essential in generating more mature hPSC-CMs. Furthermore, nanoMEA platform can be used in conjunction to effectively screen potential therapeutic targets.
METHODS
Experimental groups
RNAseq was performed on cells exposed to all different combinations of the three maturation cues: NPs, T3, and Let7i. We also included an empty vector (EV) negative control for virus exposure. For all other assays, we compared the full ComboMat platform (Let7i+NP+T3) to a viral vector Control (EV+Flat+No T3) and each maturation cue in isolation: NP (EV+NP+No T3), T3 (EV+Flat+T3), and Let7i (Let7i+Flat+No T3). The ComboMat platform utilizes nanotopographic substrate cues, thyroid hormone T3, and Let-7i microRNA (miR) overexpression at specific time-points during the culture period to induce advanced structural and phenotypic development of hPSC-CMs. Each cue was chosen to impact specific aspects of hPSC-CM development. Nanotopographic substrate cues have been shown to promote the structural maturation of primary and hPSC-CMs 14, 32 . These biophysical cues, however, have minimal impact on the metabolic development of hPSC-CMs. Therefore, thyroid hormone T3 was introduced as a biochemical cue to boost the metabolic, calcium handling, and contractile performance of the hPSC-CMs 16 . Preliminary results found, though, that long-term T3 exposure had a negative impact on sarcomere development and beat rate variability ( Supplementary   Fig. 5) , reminiscent of complications from hyperthyroidism. To counteract these detrimental effects, we sought to manipulate the transcriptome using miRs such as the Let7 family. Along with improving metabolic capacity, hypertrophy, and the genetic profile 17 , Let7i helps to regulate the expression of the Hair Growth Associated gene that acts as a transcriptional co-repressor of many nuclear receptors, including the thyroid hormone receptor.
hiPS cell line generation and maintenance
Normal urine-derived human induced pluripotent stem cells (hiPSCs) were obtained from an IRB-approved protocol as previously described 11 . Briefly, a polycistronic lentiviral vector encoding human Oct3/4, Sox2, Klf4, and c-Myc 33 was used to reprogram cells collected from clean-catch urine samples into iPSCs 11 . The derivative hiPSC line (UC3-4) was karyotyped and shown to be normal 46, XY karyotype. hiPSCs were cultured on Matrigel-coated tissue culture plastic, fed mTeSR culture medium (StemCell Technologies), and passaged using 1.9 U/mL Dispase (ThermoFisher). Cells were cultured in hypoxic conditions at 37°C, 5% CO 2 , and 5% O 2 . DMD mutant hiPSCs (UC1015-6) were generated using CRISPR-Cas9 technology to create an isogenic pair from the Normal parental line UC3-4. Briefly, guide sequences targeting the first muscle specific exon of human dystrophin were used to delete a single G base at position 263 of the dystrophin gene to create a mutant allele (Supplementary Fig. 1) . Mutation of the dystrophin gene was confirmed via sequencing. DMD mutant hiPSCs were maintained in the same manner as the Normal UC3-4 parental line.
Cardiac directed differentiation and cell culture
A monolayer-based directed differentiation protocol was used as previously described 22 . hiPSCs were dissociated into single cells using Versene (ThermoFisher) and plated at a high density (250,000 cells/cm 2 ) in mTeSR onto Matrigel-coated plates. Once a monolayer had formed, cells were treated with 1µM Chiron 99021 (Stemgent) in mTeSR until induction with 100nM Activin-A (R&D Systems) in RPMI 1640 (ThermoFisher) supplemented with B27 minus insulin (RPMI/B27/Ins-) and a switch to normoxic conditions (37°C, 5% CO 2 , ambient O 2 ) at day 0. Cardiomyocytes were then purified via metabolic challenge 34 by feeding cells DMEM without glucose, sodium pyruvate, or glutamine (ThermoFisher) containing 2% horse serum and 4 mM lactate for three days without media change. Flow cytometry for cardiac purity was performed to confirm high purity samples ( Supplementary Fig. 6 ). Afterward, hiPSC-CMs were switched back to RPMI/B27/Ins+ media containing 2 µg/mL puromycin dihydrochloride for three days to select for successfully transduced hiPSC-CMs.
Fabrication of nanopatterned substrates and nanoMEAs
Nanopatterned substrates were fabricated via capillary force lithography as previously described 35 . Polyurethane acrylate (PUA) master molds were fabricated by drop dispensing liquid PUA pre-polymer onto a deep-ion etched silicon master with the intended nanotopographic geometries (800nm wide ridges and grooves, with 600nm depth) and placing a transparent polyester (PET) film on top. The nanopattern dimensions were chosen to enhance the structure and function of hPSC-CMs (Supplementary Fig. 7) After curing under a highpowered UV light source, the PUA and PET film were peeled from the silicon master to create a PUA master mold. To create the nanopatterned cell culture substrates, a polyurethane-based UV-curable polymer (NOA76, Norland Optical Adhesive) was drop dispensed onto glass primer treated 18mm, #1 coverslips (Fisher Scientific) and the PUA master mold was placed on top.
After curing with a UV light source, the PUA master mold was peeled away, leaving behind the nanopatterned surface (NPs). Control flat substrates were fabricated using the same process but replacing the nanopatterned PUA master with an unpatterned PET film.
To prepare surfaces for cell culture, PU-based NPs and control flat substrates were washed with 70% ethanol, oxygen plasma treated at 50 W for 5 minutes, placed under a UV-C light source for 1 hour to sterilize, then incubated for 24 hours at 37°C with 5 µg/cm 2 human fibronectin (Life Technologies). hPSC-CMs were plated at a density of 150,000 cells/cm 2 .
Nanopatterned MEAs (nanoMEAs) were fabricated as described [ 
Immunofluorescent imaging and morphological analysis
After three weeks of the ComboMat platform, cells were prepared for immunofluorescent analysis by fixing in 4% paraformaldehyde (Affymetrix) for 15 minutes at room temperature.
Samples were then permeabilized with 0.1% Triton X-100 (Sigma-Aldrich) in PBS and blocked with 5% goat serum. Cells were then incubated with mouse anti-α-actinin monoclonal antibody confocal microscope with a Nikon CFI Plan Apo VC 60x water immersion objective was used to capture detailed immunofluorescent images for sarcomere analysis while a 20x air objective was used to obtain low-powered images of cells for measuring cell binucleation percentage.
Cells from both objective powers were used to measure cell size. For morphological and sarcomere analysis, hPSC-CMs were plated at 10,000 cells/cm 2 . For each condition, at least three biological specimens were plated with at least 7 cells imaged per specimen.
Quantitative sarcomere analysis
Immunofluorescent images were quantified for sarcomere alignment, pattern strength, and sarcomere length using a scanning gradient / Fourier transform script in MATLAB (Mathworks).
Each image was broken into several small segments which were individually analyzed. Using a directional derivative, the image gradient for each segment was calculated to determine the local alignment of sarcomeres. The pattern strength was then determined by calculating the maximum peaks of one-dimensional Fourier transforms in the direction of the gradient. The lengths of sarcomeres were calculated by measuring the intensity profiles of the sarcomeres along this same gradient direction. The frequency at which the intensity profiles crossed their mean allowed an accurate calculation of local sarcomere length within each image segment.
Once completed, this analysis allowed for unbiased subcellular-resolution mapping of sarcomere patterning, even in cells lacking the alignment cues provided by nanotopography.
Calcium imaging
Intracellular calcium content was measured using the ratiometric indicator dye fura2-AM as described previously 36 . In brief, cells were incubated in 0.2µM fura2-AM dye in Tyrode's solution for 20 minutes at 37°C and washed with PBS. Spontaneous Ca 2+ transients were then monitored with the Ionoptix Stepper Switch system coupled to a Nikon inverted fluorescence microscope. The fluorescence signal was acquired using a 40x Olympus objective and passed through a 510 nm filter, and the signal was quantified using a photomultiplier tube. Diastolic resting calcium concentration was quantified in the IonOptix software IonWizard using the formula: Sf2/Sb2 = ratio between the background subtracted wavelength 2 excited fluorescence in zero and saturating calcium solutions, respectively.
Electron microscopy and ultrastructural analysis
After three weeks under the ComboMat platform, hiPSC-CMs were fixed in 4% glutaraldehyde in sodium cacodylate buffer for 2 hours at room temperature for transmission electron microscopy (TEM) analysis. Samples were then washed in buffer and stained in buffered 1% osmium tetroxide for 30 minutes on ice. Next, samples were washed in water and dehydrated in a graded series of ethanol. Samples were then treated by infiltration of 1:1 ethanol:Epon-Araldite epoxy resin followed by two changes of pure Epon-Araldite. At this point, a second coverslip was placed on top of the samples in a 60°C oven for polymerization. The following day, the coverslips were dissolved using hydrofluoric acid and the samples were mounted onto blocks for sectioning. Ultra-thin (70-80 nm) axial sections of single cells were contrasted with lead citrate prior to imaging with a JEOL JEM 1200EXII at 80 kV. ImageJ (National Institutes of Health) was used to measure Z-band width as defined as the width of contiguous electrondense bands within a sarcomere structure.
MEA electrophysiological analysis
Electrophysiological analysis of spontaneously beating cardiomyocytes was collected for 2 minutes using the AxIS software (Axion Biosystems). After raw data collection, the signal was filtered using a Butterworth band-pass filter and a 90 µV spike detection threshold. Field potential duration was automatically determined using a polynomial fit T-wave detected algorithm. Beat interval analysis on 30 consecutive beats was performed as previously published 26 (see Supplemental Table 2 ).
Mitochondrial functional assay
Cellular metabolic function was measured using the Seahorse XF96 extracellular flux analyzer as previously published 17 
Contraction analysis
Our video-based contraction analysis algorithm, termed Correlation-based Contraction Quantification (CCQ), utilizes particle image velocimetry and digital image correlation algorithms 37 to track the motion of cells from bright field video recordings as previously published 22 . Functional outputs such as contraction magnitude, velocity, and angle are output as a vector field for each video frame and can be averaged spatially or temporally. In brief, a reference frame is divided into a grid of windows of a set size. To track motion, each window is run through a correlation scheme comparing a second frame, providing the location of that window in the second frame. The correlation equation used provided a Gaussian correlation peak with a probabilistic nature that provides sub-pixel accuracy. The videos used for this analysis were taken with a Nikon camera at 20x magnification and 30 frames per second.
RNA-seq analysis
Total RNA was extracted using trizol (Thermo Fisher Scientific) from RUES2 hESC-CMs. RNAseq samples were aligned to hg19 using Tophat (PMID: 19289445, version 2.0.13). Gene-level read counts were quantified using htseq-count (PMID: 25260700) using Ensembl GRCh37 gene annotations. Genes with total expression above 3 RPKM summed across RNA-seq samples were kept for further analysis. princomp function from R was used to for Principal Component Analysis. DESeq (PMID: 20979621) was used for differential gene expression analysis. Genes with fold change >1.5 were considered differentially expressed. topGO R package (PMID:
16606683) was used for Gene Ontology enrichment analysis.
For the heat map of pathway enrichment, each condition was compared against the Control (EV-Flat) condition, and up-regulated genes (>1.5 fold change) and down-regulated genes were identified (< -1.5 fold change). Hypergeometric test was performed on up-and down-regulated genes separately for enrichment against a curated set of pathways that are beneficial for cardiac maturation, resulting in a m by n matrix, where m is the number of pathways (m=7) and n is the number of conditions (n=10). The negative log10 of the ratio between enrichment p-value for up-and down-regulated genes were calculated to represent the overall net "benefit" of a treatment: large positive value (>0) means the treatment results in more up-regulation of genes in cardiac maturation pathways than down-regulation of these genes, and more negative values means the treatment results in more down-regulation of genes in cardiac maturation pathways.
Flow cytometry
Cells were dissociated and prepared for flow cytometry before and after lactate purification and puromycin selection to determine selection efficiency. Cells were first fixed in 4% paraformaldehyde for 15 minutes. Cells were then permeabilized with 0.75% Saponin and stained in PBS containing 5% FBS with either 1:100 mouse anti-cTnT or isotype control mouse IgG antibodies. Alexa-488 conjugated goat-anti-mouse secondary antibody (1:200, Invitrogen) was used for visualization. Samples were run on a BD Sciences FACS Canto flow cytometer and analyzed with FlowJo software. 
High-throughput drug screening
Statistical analyses
Statistical significance between groups was determined using either a One-Way or Two-Way 
